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Since determination of themyoglobin structure in 1957, X-ray crystallography, as the anchoring tool
of structural biology, has played an instrumental role in deciphering the secrets of life. Knowledge
gained through X-ray crystallography has fundamentally advanced our views on cellular processes
and greatly facilitated development of modern medicine. In this brief narrative, I describe my
personal understanding of the evolution of structural biology through X-ray crystallography—using
as examples mechanistic understanding of protein kinases and integral membrane proteins—and
comment on the impact of technological development and outlook of X-ray crystallography.Brief History
When Wilhelm Roentgen discovered X-ray in 1895, he could not
have imagined the powerful applications of X-ray diffraction on
crystals of biological samples. Max von Laue showed X-ray
diffraction pattern of crystals in 1912, and William Lawrence
Bragg derived a general equation, known as the Bragg’s Law,
to describe the founding principle of image formation by X-ray
diffraction (Bragg, 1913) (Figure 1). James Sumner obtained
the first crystal of jack bean urease in 1926 and showed the
enzyme to be a protein (Figure 1). Max Perutz and John Kendrew
decided to pursue crystal structures of proteins—hemoglobin
and myoglobin—beginning in the 1940s at the Cavendish Labo-
ratory, University of Cambridge. Their pioneering effort was
encouraged by William Lawrence Bragg, who served as the Di-
rector of the Cavendish Laboratory between 1938 and 1954. In
1953, James Watson and Francis Crick, both employed at the
Cavendish Laboratory, deduced a DNA double-helix model on
the basis of X-ray fiber diffraction images of DNA generated by
Rosalind Franklin (Watson and Crick, 1953).
The entire biological research community was both excited
and shocked to see the very first crystal structure of amacromol-
ecule in 1957—that of sperm whale myoglobin by John Kendrew
(Kendrew et al., 1958). The structure of myoglobin, initially deter-
mined at 6 A˚ resolution but quickly improved to 2 A˚ (Kendrew
et al., 1960), confirmed the a-helical conformation as proposed
by Linus Pauling and Robert Corey (Pauling and Corey, 1951a,
1951b, 1951c; Pauling et al., 1951). Kendrew’s success in struc-
ture determination of myoglobin was indispensably assisted by
Perutz’ solution to the phase problem—multiple isomorphous
replacement through heavy atom soaks. Max Perutz presented
his own X-ray structure on the larger protein hemoglobin at
5.5 A˚ (Perutz et al., 1960) and took a few years to improve the res-
olution to 2.8 A˚ (Perutz et al., 1968a, 1968b). Kendrew founded
the Journal of Molecular Biology and served as Editor-in-Chief
for a number of years. Kendrew also helped establish the Euro-
pean Molecular Biology Laboratory in Heidelberg and became
its founding director. Perutz, on the other hand, founded anddirected the MRC Laboratory of Molecular Biology (Figure 1).
Notably, the double-helix structure of DNA was finally visualized
in 1980 by the X-ray structure of a 12-base-pair palindromic
DNA, known as the Dickerson dodecamer (Wing et al., 1980).
DNA is the genetic material of almost all living matters, and
proteins are the engines of life. Structural elucidation of DNA
and protein is arguably the most important scientific discovery
in the 20th century. Proposal of the double-helix structure of
DNA has fundamentally changed our perception of life and has
ushered in a new era of modern biology. Crystal structures of
myoglobin and hemoglobin allowed us to link protein function
to its chemical details. In many respects, the atomic details
offered by X-ray crystallography allowed mechanistic under-
standing of protein function, which marks the beginning of mo-
lecular biology. Kendrew and Perutz have been fondly named
fathers of molecular biology.
Early crystallographic studies focused on abundant proteins,
most often enzymes, from animal organs and tissues. Following
the successes on myoglobin and hemoglobin, structural infor-
mation was obtained for at least seven additional proteins in
the 1960s, including the first enzyme hen egg white lysozyme
(Blake et al., 1965), ribonucleases A and S (Kartha et al., 1967;
Wyckoff et al., 1967), chymotrypsin (Matthews et al., 1967),
papain (Drenth et al., 1968), carboxypeptidase A (Lipscomb
et al., 1969), and subtilisin (Wright et al., 1969). These structures,
together with those of many other enzymes in the 1970s and
beyond, reveal the active site conformations and catalytic mech-
anisms, which form the physical basis of molecular enzymology.
The Protein Data Bank (PDB), a central repository for three-
dimensional structural data of macromolecules, was established
in 1971 at the Brookhaven National Laboratory with seven initial
entries. As of August 26, 2014, there were 102,863 total entries
in the PDB, of which 88.7%were determined by X-ray crystallog-
raphy, 10.3% by nuclear magnetic resonance (NMR), and 0.8%
by electron microscopy (EM) (Figure 2A). Following structure
determination of the lysozyme from bacteriophage T4 (T4 lyso-
zyme) (Matthews and Remington, 1974), it became a paradigmCell 159, November 20, 2014 ª2014 Elsevier Inc. 995
Figure 1. The History of X-Ray Crystallog-
raphy in the Eyes of Nobel Prizes
Major achievements in the development and appli-
cation of X-ray crystallography have been recog-
nized by at least 14 Nobel Prizes. The first Nobel
Prize in physics was awarded to Roentgen in 1901
for his discovery of X-rays. The next two Nobel
Prizes in 1914 and 1915 were given to Laue for his
discovery of X-ray diffraction by crystals and to the
Bragg father and son for the use of X-rays to
determine crystal structure. Sumner was awarded a
Chemistry Prize in 1946 for crystallization of the
enzyme urease. Pauling won a Chemistry Prize in
1954 for his research into the nature of chemical
bond and its application in structure determination.
The year 1962 was quite special, with the Chemistry
Prize awarded to Kendrew and Perutz for their
pioneering work in protein structure determination,
and the Physiology or Medicine Prize bestowed on
Crick, Watson, and Wilkins for their contribution in
the discovery of DNA structure. Hodgkin was
awarded a Chemistry Prize in 1964 for structural
elucidation of many biochemical substances,
including vitamin B12. The next six Nobel Prizes
were awarded to macromolecular crystallogra-
phers: Deisenhofer, Huber, and Michel in 1988 for
the structure of bacterial photosynthetic reaction
center; Walker in 1997 for the structure of F1-
ATPase; MacKinnon in 2003 for potassium chan-
nels; Kornberg in 2006 for the structure of RNA
polymerases; Ramakrishnan, Steitz, and Yonath in
2009 for the structure of ribosome; and Kobilka in
2012 for the structure of GPCR. Listed in the lower
left corner are nine Nobel Prizes that are closely
related to X-ray crystallography.
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Figure 2. Entries in the Protein Data Bank
Have Enjoyed Near-Exponential Growth in
the Past 30 Years
(A) The total number of entries of PDB. The PDB
was established in 1971 at the Brookhaven Na-
tional Laboratory with only seven entries. The total
number of entries grew to 69 in 1980, 507 in 1990,
13,597 in 2000, and 70,039 in 2010. As of August
26, 2014, there were 102,863 total entries in the
PDB, of which 88.7% were determined by X-ray
crystallography, 10.3% by NMR, and 0.8%by EM.
Some of the representative X-ray structures are
indicated in the chart.
(B) The total number of unique membrane protein
structures in PDB. In sharp contrast to their heavy
presence, structures of membrane proteins only
account for just over 1% of all entries in the PDB,
with 1,520 total entries and 499 unique structures
as of August 31, 2014 (http://blanco.biomol.uci.
edu/mpstruc/).for the study of protein folding and thermodynamics (Baase
et al., 2010). In addition to the study of enzymes, viruses became
hotly pursued in the 1960s and 1970s. Following his pioneering
research into the tomato bushy stunt virus (Harrison, 1969; Har-
rison and Jack, 1975), Stephen Harrison and colleagues re-
ported the first virus structure at an atomic resolution of 2.9 A˚,
revealing 180 copies of the capsid protein arranged in an icosa-
hedral particle (Harrison et al., 1978) (Figure 2A). Aaron Klug and
colleagues solved the X-ray structure of the TMV protein disk at
2.8 A˚ resolution (Bloomer et al., 1978) and obtained a low-reso-
lution structure of nucleosome core particle (Finch et al., 1977;
Richmond et al., 1984).
Two exciting developments in biology—discovery of gene
regulation in the 1960s and emergence of recombinant DNACell 159, Ntechnology in the late 1970s—raised the
question of how DNA sequences could
be specifically recognized by transcrip-
tion factors. Seeking an answer to this
question became an important theme
for structural biology in the 1980s (for
more details, please see Cramer [2014]
in this issue of Cell). Many DNA-binding
motifs were identified, and a number of
crystal structures of protein-DNA com-
plexes were elucidated (Aggarwal et al.,
1988; Anderson et al., 1987; Otwinowski
et al., 1988; Wolberger et al., 1988). There
were many other exciting developments
in the 1980s. Michael Rossmann’s group
determined the first atomic resolution
crystal structure of a human common
cold virus (Rossmann et al., 1985) (Fig-
ure 2A). These early findings were fol-
lowed up with a barrage of structural
information on viruses, including mengo
virus (Luo et al., 1987) and foot-and-
mouth disease virus (Acharya et al.,
1989). Due to impending health threats,
disease-causing viruses continue toattract ample attention from the structural biology community.
Insights gained from these virus structures have, in turn, revolu-
tionized our concepts of virology and helped vaccine design and
drug discovery. The 1980s also marks the beginning of structural
biology on integral membrane proteins, with determination of
atomic resolution X-ray structures of the bacterial photosyn-
thetic reaction center (Allen et al., 1987; Deisenhofer et al., 1985).
Compared to the 1980s, paces of structural biology were
considerably faster in the 1990s. The total number of PDB entries
increased from less than 400 at the beginning of the year 1990 to
more than 13,000 by the end of the year 2000 (Figure 2A). Cellular
signal transduction was the principal focus of biological investi-
gation in the 1990s; consequently, the central theme of structural
biology during this period was mechanistic understanding of cellovember 20, 2014 ª2014 Elsevier Inc. 997
signaling. Crystal structures were elucidated for numerous
signalingmotifs, exemplified by the phosphotyrosine recognition
SH2 domain (Waksman et al., 1992), the phosphoinositol-bind-
ing PH domain (Ferguson et al., 1995), the proline-rich sequence
binding SH3 domain (Musacchio et al., 1992, 1994), and the
carboxyl-terminal peptide-binding PDZ domain (Doyle et al.,
1996). The modular nature of these motifs and characterization
of their binding specificities constitute an important basis for
the development of synthetic biology and chemical biology.
Signal transduction often begins in the extracellular spacewith
ligand binding to its cell-surface receptor. Crystal structure of the
complex between human growth hormone and the extracellular
domain of its receptor revealed a single hormone molecule
recognized by two molecules of receptor (de Vos et al., 1992)
(Figure 2A). Some of the other early cocrystal structures include
the extracellular domain of TNF receptor bound to TNF-b (Ban-
ner et al., 1993), the extracellular fragment of interferon-g recep-
tor bound to interferon-g (Walter et al., 1995), and domain 2 of
the Flt-1 receptor bound to VEGF (Wiesmann et al., 1997). These
ligand-receptor structures give rise to the principle that receptor
clustering induced by ligand binding serves as a platform for
signaling, which usually involves phosphorylation by receptor ki-
nases. Crystal structure of the catalytic subunit of protein kinase
A (PKA)—the first for a protein kinase—revealed an amino-termi-
nal lobe rich in b strands and a carboxyl-terminal lobe with
mostly a helices (Knighton et al., 1991) (Figure 2A). The kinase
fold observed in PKA was soon confirmed by dozens of crystal
structures of other important protein kinases in the 1990s. Un-
derstanding of immune signaling by the T cell receptor (TCR)
is markedly enhanced by structures of TCR and their complexes
with MHC-peptide antigens (Garboczi et al., 1996; Garcia et al.,
1996) (Figure 2A).
Structural biology of membrane proteins enjoyed rapid devel-
opment in the 1990s and beyond. As an extension of X-ray crys-
tallography, electron crystallography was successfully applied
to determine the structure of membrane proteins that formed
two-dimensional crystals at low resolution in the 1980s and
near-atomic resolution in the 1990s. Following two decades of
method development on electron crystallography (Subramaniam
et al., 2002), Richard Henderson and colleagues succeeded in
the elucidation of a 3.5 A˚ resolution structure of bacteriorho-
dopsin using electron diffraction data (Grigorieff et al., 1996).
Ku¨hlbrandt and colleagues generated a 3.4 A˚ resolution struc-
ture of a plant light-harvesting complex (Ku¨hlbrandt et al.,
1994). A striking 1.9 A˚ resolution was achieved for two-dimen-
sional aquaporin-0 crystals, which allowed clear visualization
of lipid-protein interactions (Gonen et al., 2005).
X-ray structure of the mitochondrial F1-ATPase at 2.8 A˚ res-
olution revealed distinct conformations for the three catalytic b
subunits (Abrahams et al., 1994). Structural analysis of a bacte-
rial potassium channel—the first structure of a recombinant in-
tegral membrane protein—provided insights into potassium
conduction and selectivity (Doyle et al., 1998). This work was
followed up with systematic structural studies of potassium
channels, which offer molecular explanations for gating of the
ion-conducting pore (MacKinnon, 2003). X-ray structure of the
bacterial large-conductance mechanosensitive channel (MscL)
revealed a homopentameric assembly and served as a founda-998 Cell 159, November 20, 2014 ª2014 Elsevier Inc.tion for understanding other mechanosensitive channels (Chang
et al., 1998) (Figure 2B). Structural analysis of the water channel
aquaporin-1 identified a tetrameric assembly with water mole-
cules localized along a selectivity filter (Figure 2B) (Sui et al.,
2001). Crystal structure of the AMPA-type GluA2 receptor re-
vealed a 2-fold symmetry in the extracellular domain and a
4-fold symmetry in the membrane-spanning ion channel domain
(Sobolevsky et al., 2009). The first crystal structures on recom-
binant membrane transporters were elucidated for the lactose
permease LacY (Abramson et al., 2003) and the glycerol-3-
phosphate transporter GlpT (Huang et al., 2003), defining a
conserved fold for the major facilitator superfamily (MFS) of sec-
ondary active transporters (Figure 2B). Crystal structure of the
human glucose transporter GLUT1—the first eukaryotic MFS
structure—allows rationalization of disease-derived mutations
(Deng et al., 2014). Following an early X-ray structure on bovine
rhodopsin (Palczewski et al., 2000), crystal structures of the re-
combinant G-protein-coupled receptor (GPCR) were reported
on b2 adrenergic receptor (Cherezov et al., 2007; Rasmussen
et al., 2007). Structure of an agonist-bound b2 adrenergic re-
ceptor in complex with a nucleotide-free Gs heterotrimer
provided a preliminary answer to how ligand binding to GPCR
triggers the activation of G protein in the cytoplasm (Rasmussen
et al., 2011).
Improvement of hardware and software in X-ray crystallog-
raphy has greatly accelerated the pace of discovery and em-
boldened structural biologists to attack challenging research
projects. Structural elucidation of the proteasomal 20S particles
revealed the architecture and identified the proteolytic mecha-
nisms (Groll et al., 1997; Lo¨we et al., 1995; Seemu¨ller et al.,
1995) (Figure 2A). Crystal structure of the GroES-GroEL complex
markedly improved our understanding of chaperone-assisted
protein folding (Xu et al., 1997b), whereas structural analysis of
the nucleosome core particle shows in atomic detail how 146
base pairs of DNA are assembled around the histone octamer
(Luger et al., 1997) (Figure 2A). Crystal structure of the large ribo-
somal subunit, including 2833 RNA nucleotides and 27 proteins,
was determined at an atomic resolution of 2.4 A˚ (Ban et al., 2000)
and expanded our protein-RNA recognition database as of the
year 2000 by a factor of 6-fold. Since the early 1990s, biologically
important megacomplexes and macromolecular assemblies
have represented increasingly attractive targets for structural
biologists. X-ray structures of the eukaryotic exosomes have re-
vealed important insights into the degradation and processing of
cellular RNA (Bonneau et al., 2009; Liu et al., 2006; Makino et al.,
2013; Wasmuth et al., 2014). Preliminary structural analysis of
the U1, U4, and U6 snRNPs, three subcomplexes of the eukary-
otic spliceosome, provided mechanistic insights into mRNA
slicing (Leung et al., 2011; Montemayor et al., 2014; Pomeranz
Krummel et al., 2009; Zhou et al., 2014). Crystal structure of
the human COP9 signalosome revealed molecular architecture
of the eight-subunit complex (Lingaraju et al., 2014). The combi-
nation of X-ray crystallography with single-particle cryo-EM
analysis has been routinely used to provide accurate information
onmegacomplexes, as exemplified by structure of the yeast 26S
proteasome (Beck et al., 2012).
The vast amount of information in the PDB serves as the struc-
tural basis for understanding biology and innovating medicine.
X-ray crystallography as a tool has played a dominant role in the
past five decades in deciphering the molecular mechanisms of
virtually all biological processes. It is truly a mission impossible
to attempt coverage of, even if just glossing over, all major
achievements of structural biology. Because this narrative is tar-
geted to a general readership, the goal is to showcase the spirit
of structural biology through brief description of representative
examples—how X-ray crystallography has helped transform
the understanding of biology. Therefore, I will mainly comment
on two areas of biological research that have been galvanized
by X-ray crystallography: kinase regulation and membrane pro-
tein structure-function relationship (for the areas of chromatin
and transcription, please see Cramer [2014] in this issue of
Cell). Within each research area, the focus is not to provide a
comprehensive review but to discuss pioneering structural
investigation and select follow-up studies.
Kinases and Anticancer Drugs
cAMP-Dependent PKA
Reversible protein phosphorylation was discovered on glycogen
phosphorylase in the 1950s by Edwin Krebs, Edward Fischer,
Earl Sutherland, and Wosilait (Fischer and Krebs, 1955; Suther-
land and Wosilait, 1955). The first essential step in glycogen
metabolism—its phosphorylation—is mediated by glycogen
phosphorylase, whose activation depends on phosphorylase
kinase. The conversion of inactive phosphorylase kinase to its
activated form is mediated by phosphorylase kinase kinase,
also known as cyclic AMP (cAMP)-dependent protein kinase,
or PKA. The catalytic subunit of PKA in its free form is catalyti-
cally active; however, two molecules of the catalytic subunits
are constitutively bound and inhibited by a homodimer of regula-
tory subunits. Binding of the second messenger cAMP to the
regulatory subunits results in the dissociation and hence activa-
tion of the PKA catalytic subunits.
Human genome is predicted to encode 518 putative protein ki-
nases, which, on the basis of substrate specificity, are classified
into 90 tyrosine kinases (PTKs) and 428 serine/threonine kinases
(PSKs). These kinases play an essential role in virtually all cellular
processes. The very first atomic view on any protein kinase was
provided in 1991 by the crystal structure of the catalytic subunit
of PKA (Knighton et al., 1991). This structure reveals a general
architecture of two lobes, with the substrate-binding site and
the ATP-binding pocket both located between the two lobes
(Figure 3A). An activation helix (aC), which contains a catalytic
triad residue, and an activation loop, whose phosphorylation re-
sults in the activation of the kinase, are positioned next to the
hinge between the two lobes. These structural features become
the hallmarks of nearly all protein kinases.
Structures of the catalytic subunit of PKA explain substrate
specificity and define conformational flexibility (Knighton et al.,
1991). Structural analysis of the regulatory subunit revealsmech-
anism of cAMP recognition (Su et al., 1995). Subsequent struc-
tural analysis of PKA with both catalytic and regulatory subunits
provides a molecular explanation for the inhibition of PKA and
identifies amodel for cAMP-mediated activation through binding
to the regulatory subunit (Figure 3B) (Kim et al., 2005; Wu et al.,
2007). A 2.3-A˚ X-ray structure of the intact, tetrameric PKA
holoenzyme yields insights into allosteric regulation and hasramifications for understanding the regulation of other con-
served kinases (Figure 3C) (Zhang et al., 2012).
Cyclin-Dependent Kinases
The temporal-spatial activities of cyclin-dependent kinases
(CDKs) determine the fate of the cell cycle and thus are subject
to complex regulation. Unlike most kinases, which are active in
their free forms, free CDKs are inactive and only attain a basal
level of catalytic activity upon association with cyclin. The basal
activity can be greatly stimulated by phosphorylation of the acti-
vation loop (also known as T loop). The Cip/Kip family of cell-cy-
cle inhibitors, exemplified by p27, potently inhibits the kinase
activity of the assembled cyclin-CDK complexes, whereasmem-
bers of the INK4 inhibitor family can bind the inactive, free CDK,
thus preventing its activation. The INK4 inhibitors, exemplified by
p16INK4a, also bind and inhibit active cyclin-CDK complexes.
Crystal structure of free CDK2 reveals a misaligned confor-
mation for the activation helix (PSTAIRE helix) and the T loop,
providing an immediate explanation to the lack of catalytic activ-
ity for the free kinase (De Bondt et al., 1993). Binding by cyclin A
induces large conformational changes in the PSTAIRE helix and
T loop, resulting in correct alignment of the active site residues
and opening of the catalytic cleft (Jeffrey et al., 1995). Phosphor-
ylation of CDK2 in the T loop results in the reorganization of the
local structural elements, priming it for substrate binding (Russo
et al., 1996b). Remarkably, the inhibitory domain of p27Kip1
adopts an extended conformation to interact with both cyclin A
and CDK2, with an invariant residue inserting into the catalytic
cleft of CDK2 and displacing ATP (Russo et al., 1996a). By
contrast, the INK4 inhibitors p16INK4a and p19INK4d bind close
to the ATP-binding site of CDK6 and cause structural changes
in the catalytic cleft to negatively affect the kinase activity (Broth-
erton et al., 1998; Russo et al., 1998). The binding site for
p16INK4a or p19INK4d is opposite of where cyclin binds, explaining
why the INK4 inhibitors can bind both free and cyclin-bound
CDKs.
Advent of structural information onCDKs greatly facilitated the
screening and design of specific small-molecule inhibitors that
block their kinase activities. These inhibitors, mostly ATP ana-
logs, effectively stopped cancer cell growth in petri dish and in
animal models. The outcome of anticancer clinical trials thus
far has been less than desirable, with notable toxicity and mar-
ginal efficacy. For example, flavopiridol exhibited multifaceted,
antiproliferative effects in preclinical research but had disap-
pointing performance in clinical trials with narrow therapeutic
window and off-target effects. The more selective, second gen-
eration CDK inhibitor dinaciclib has entered phase III clinical trial.
A notable advance is the development of palbociclib, a highly se-
lective inhibitor of CDK4 and CDK6, for treatment of the HER2/
ER+ breast cancer. In addition, the problem of cross-reactivity
by ATP analogs can be effectively dealt with by the development
of inhibitors that target sites other than the ATP-binding pocket
(Abate et al., 2013).
BCR-ABL, EGFR, and Other Kinase Targets
BCR-ABL is the fusion product of chromosome translocation—a
portion of the Bcr gene on chromosome 22 is fused to the Abl
tyrosine kinase gene on chromosome 9 in the Philadelphia chro-
mosome. BCR-ABL is constitutively activated and drives the
development of chronic myelogenous leukemia (CML). PerhapsCell 159, November 20, 2014 ª2014 Elsevier Inc. 999
Figure 3. Kinase Structure, Regulation, and
Inhibitors
(A) Crystal structure of the catalytic subunit of
protein kinase A (PKA, PDB code 1ATP, colored
green). The activation helix (aC helix) in the N lobe
is colored purple, and the activation loop (T loop) is
highlighted in red. ATP and phosphothreonine 198
(Thr198) in the T loop are indicated. The substrate
analog inhibitor is represented in gray.
(B) Crystal structure of the complex between PKA
catalytic subunit and regulatory subunit (PDB
code 3FHI). The PKA catalytic and regulatory
subunits are colored green and blue, respectively.
The ATP analog AMP-PNP is shown in sticks. The
inhibitory region of the regulatory subunit is rep-
resented in gray.
(C) Mechanism of cAMP-mediated activation of
PKA. In the absence of cAMP, two catalytic sub-
units (green) and two regulatory subunits (blue)
assemble into an inactive, tetrameric PKA holo-
enzyme (PDB code 3NTP). The binding of cAMP to
the regulatory subunits causes pronounced
conformational changes, leading to dissociation of
the catalytic subunits and producing a dimeric
cAMP-bound regulatory subunits (PDB code
4MX3) and two free active catalytic subunits (PDB
code 1ATP).
(D) Small-molecule inhibitors of BCR-ABL as
potent anticancer drugs. Crystal structure of the
human ABL1 kinase domain bound to the anti-
cancer drug imatinib (PDB code 2HYY) is shown in
the left panel. Imatinib is a potent drug targeting
CML through binding and inhibition of BCR-ABL.
Two other inhibitors, nilotinib and dasatinib, are
used to treat CML patients with imatinib-resistant
mutations. The three small molecule inhibitors are
shown in the right panel.the most celebrated, anticancer kinase inhibitor is imatinib, also
known as gleevec or STI-571, which targets BCR-ABL (Shah and
Sawyers, 2003). Nearly all chronic myelogenous leukemia (CML)
patients who took the drug in the first phase I trial in 1998 were
responding; imatinib was approved by FDA in 2001. Imatinib
also potently inhibits the tyrosine kinases c-kit and PDGFR,
and its clinical use has been approved for a few other cancer
types associated with c-kit or PDGFR activation. Crystal struc-1000 Cell 159, November 20, 2014 ª2014 Elsevier Inc.tures reveal the precise interactions of
an imatinib variant with surrounding resi-
dues in the ATP-binding pocket of BCR-
ABL and explain how patient-derived
mutations (such as T315I) inactivate ima-
tinib binding (Figure 3D) (Nagar et al.,
2002; Schindler et al., 2000). Imatinib,
classified as a type II kinase inhibitor,
binds the kinase in its inactive DFG-out
conformation. The structural information
guided subsequent development of sec-
ond-generation inhibitors that stabilize
these kinase-specific inactive conforma-
tions. These inhibitors include ponatinib,
which is effective against the T315I muta-
tion, and nilotinib (sometimes known as
super gleevec, Figure 3D), which works
well against the majority of CML muta-tions (except T315I). The structural information also helped
design of the type I kinase inhibitors, exemplified by dasatinib
(Figure 3D), which bind the kinase in its active DFG-in confor-
mation. These second-generation inhibitors are used to treat
relapsed CML patients with imatinib-resistant mutations.
The epidermal growth factor receptor (EGFR) family of recep-
tor tyrosine kinases (RTK) has four members ErbB1–4, each with
an extracellular ligand-binding domain, a single transmembrane
segment, and an intracellular kinase domain. The activation
mechanism of EGFR has been elegantly revealed by crystallo-
graphic discovery and subsequent biochemical analysis
(Burgess et al., 2003; Zhang et al., 2006). Growth factor binding
induces conformational changes in the extracellular domain,
leading to its dimerization with the two ligands on opposite sides
of the heterocomplex (Garrett et al., 2002; Ogiso et al., 2002). The
EGFR kinase domain exists in an autoinhibited conformation,
with key residues Leu834 and Leu837 stabilizing the inactive
conformation of the aC helix. Receptor dimerization, induced
either by ligand binding or by high protein concentrations during
crystallization, facilitates formation of an asymmetric dimer,
where the C-lobe of the activator kinase interacts with the
N-lobe of the receiver kinase, leading to allosteric activation of
the latter (Zhang et al., 2006). The structural observations also
provide a satisfying explanation to how mutations of Leu834/
Leu837 drive EGFR activation. Aberrant activation of EGFR con-
tributes to the development of a number of malignant cancer
types. A few small-molecule inhibitors of EGFR have been
used in the clinic to treat cancers, such as gefitinib (popularly
known as Iressa) for treating non-small-cell lung cancer
(NSCLC). Patients with activating mutations in EGFR respond
very well to the treatment of gefitinib (Lynch et al., 2004; Paez
et al., 2004). Other small-molecule inhibitors targeting EGFR
include lapatinib for breast cancer and erlotinib (or Tarceva) for
NSCLC and pancreatic cancer.
Monoclonal antibodies have also been developed to prevent
ligand binding to EGFRs or to sabotage dimerization of the extra-
cellular domain. Herceptin, or trastuzumab, which blocks ligand
binding by associating with the extracellular domain of ErbB2/
HER2 (Cho et al., 2003), proved to be effective in treating
ErbB2-overexpressing breast cancer (Recondo et al., 2014).
Pertuzumab, on the other hand, prevents receptor dimerization
by binding to the extracellular domain of ErbB2/HER2 (Franklin
et al., 2004). Cetuximab, or Erbitux, which prevents both ligand
binding and receptor dimerization through binding to domain III
of the EGFR extracellular region (Li et al., 2005), has been
approved for the treatment of metastatic colon cancer, NSCLC,
and head and neck cancer. More recently, monoclonal antibody
and cytotoxic small molecule have been combined into a single
entity, named antibody-drug conjugates, which directly target
cancer cells with high-dose chemotherapy. Trastuzumab em-
tansine (or Kadcyla) is such an antibody-drug conjugate that
combines trastuzumab and the cytotoxic agent mertansine; it
is approved to treat HER2-positive metastatic breast cancer
(Recondo et al., 2014).
Chemical Genetics of Protein Kinases
The structural information not only facilitated drug discovery
targeting various malignancies but also gave birth to chemical
genetics on kinases. The proto-oncogene c-Src, discovered by
J. Michael Bishop and Harold Varmus, exists in normal cells in
an inactive conformation. In the crystals of autoinhibited c-Src,
the SH3 domain, the SH2 domain, and the kinase domain
interact with each other to assemble into a tightly folded assem-
bly in which the phosphorylated Tyr527 binds to the SH2 domain
and locks c-Src in an inactive conformation (Sicheri et al., 1997;
Xu et al., 1997a). Activation of the c-Src pathway, triggered by
dephosphorylation of Tyr527, contributes to multiple cancertypes. On the basis of structural modeling, the ATP-binding
site of v-Src was mutated such that the resulting v-Src, but not
the wild-type (WT) v-Src, could accept a synthetic ATP analog
(Shah et al., 1997). The engineered v-Src displayed similar cata-
lytic efficiency, as well as substrate specificity as the WT v-Src,
but allowed direct tracing of v-Src substrates in cells (Shah et al.,
1997). This strategy was applied to other Src family members
and general protein kinases. The engineered kinases, along
with the unique ATP analogs, allowed investigation of important
biological questions, such as identification of Cdk1 targets in
yeast, selective inhibition of neurotrophin in vivo, and discovery
of JNK2 as a positive regulator of c-Jun.
Membrane Protein Structure and Function
Membranes compartmentalize cellular processes and enzy-
matic reactions, and membrane proteins account for 20%–
30% of all human proteins. Structures of membrane proteins,
however, only account for just over 1% of all entries in the
PDB, with 1,520 total entries and 499 unique structures as of
August 31, 2014 (Figure 2B). The structural investigation ofmem-
brane proteins had been hampered by the technical challenges
of poor recombinant expression, insolubility in aqueous solution,
and unruly behavior in detergent solubilized forms. In addition,
crystals of membrane protein usually diffract X-rays poorly.
Consequently, structural biology of membrane proteins lagged
behind that for soluble proteins by two decades.
Early effort focused on endogenous membrane proteins,
eliminating the hassles of recombinant expression. Crystal
structure of a bacterial photosynthetic reaction center at 3 A˚
resolution—the first atomic-resolution image of any integral
membrane protein—reveals the stunning inner workings usually
buried within the membrane (Deisenhofer et al., 1985) (Figure 1).
X-ray structure of the F1-ATPase from bovine heart mitochon-
dria, determined at 2.8 A˚ resolution, captured the three catalytic
b subunits in distinct conformations and different states of
nucleotide binding (Abrahams et al., 1994) (Figure 1). This struc-
tural observation lends critical support to the hypothesis that
the three catalytic subunits are at different states of the cata-
lytic cycle at any moment, and rotation of the a3b3 subcomplex
relative to the g subunits results in the interconversion of the
states.
Roderick McKinnon was among the first to use recombinant
system to express membrane proteins—potassium channels—
for structural studies (Figure 1). Despite similar properties be-
tween potassium (K+) and sodium (Na+), K+ channels are at least
four orders of magnitude more permeant for K+ than for Na+.
Crystal structure of the K+ channel from Streptomyces lividans
(KcsA) at 3.2 A˚ resolution revealed the first atomic view of an
ion channel (Figure 4A) (Doyle et al., 1998). Tetrameric arrange-
ment of the K+ selectivity filter and structural features of the
pore provide explanations to ion selectivity and conduction
(Doyle et al., 1998; Roux and MacKinnon, 1999; Zhou et al.,
2001). Only two out of four potential K+ binding sites are occu-
pied in the selectivity filter, allowing energy minimization and
optimization of conduction rate (Morais-Cabral et al., 2001).
Subsequent structural and biochemical studies on K+ channels
uncoveredmechanistic insights into gating of the ion-conducting
pore (Jiang et al., 2002, 2003; Long et al., 2005).Cell 159, November 20, 2014 ª2014 Elsevier Inc. 1001
Figure 4. Structures and Mechanisms of Representative Channels
(A) Crystal structure of the potassium channel KcsA (PDB code: 1BL8). KcsA is
a homotetramer. Each subunit contains two a helices connected by the pore
region, which harbors the selectivity filter. The selectivity filter is shown in a
close-up view, with three K+ ions (magenta spheres) identified. Two K+ ions are
in a rapid equilibrium, with only one of the lower two positions occupied at any
instant. One water molecule is shown in red sphere.
(B) Crystal structure of the water channel aquaporin 1 (AQP1) (PDB code:
1J4N). AQP1 is a tetramer with each subunit providing an independent water
pore. Four water molecules (red spheres) are located at three hydrophilic
nodes along the selectivity filter.
(C) Crystal structure of the mechanosensitive channel MscL (PDB code:
2OAR). MscL is organized as a homopentamer. A water-filled opening from the
extracellular side narrows at the cytoplasmic side, where hydrophilic residues
may function as the selectivity filter.
(D) Crystal structure of the AMPA-type glutamate receptor GluA2 (PDB code:
3KG2). The GluA2 structure is a homotetramer. In the antagonist-bound
structure, the ion channel adopts a closed conformation. Residues forming the
narrowest region are indicated in the close-up view.
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GPCRs define a large family of seven transmembrane proteins
that mediate a wide range of signaling at the plasma membrane.
Approximately half of all clinical drugs directly target GPCRs.
Working with Robert Lefkowitz, Brian Kobilka cloned and bio-
chemically characterized humana2- and b2-adrenergic receptors
(Kobilka et al., 1987a, 1987b, 1988). X-ray structure of bacterio-
rhodopsin, which bears homology to mammalian GPCR, was
determined in 1997 (Pebay-Peyroula et al., 1997), followed by
the structure determination of bovine rhodopsin (Palczewski
et al., 2000). Conformation of the seven transmembrane helices
(TMs) in bovine rhodopsin differs significantly from that in bacte-
riorhodopsin. Kobilka and colleagues determined the crystal
structure of the human b2 adrenergic receptor (b2AR) at 3.4–
3.7 A˚ resolution (Rasmussen et al., 2007). The relatively poor
X-ray diffraction of b2AR crystals was successfully mitigated by
insertion of T4 lysozyme into the third intracellular loop (Rose-
nbaum et al., 2007). Crystal structure of the resulting b2AR bound
to a diffusible ligand carazolol was determined at 2.4 A˚ resolution,
revealing extensive interactions of carazolol with residues at
the ligand-binding site (Cherezov et al., 2007). Structures of
activated and/or agonist-bound, as well as antagonist-bound,
GPCRs reveal distinct conformations of the ligand-binding
pocket. The most notable ligand-induced conformational change
on the cytoplasmic side appears to be an outward movement of
the cytoplasmic portion of TM5 and TM6. A wealth of rapidly
emerging structures on GPCRs has greatly stimulated the inter-
ests of major pharmaceutical companies to improve existing
drugs and to screening and design new therapeutic modulators.
The principal biological question on GPCR is how conforma-
tional changes triggered by ligand binding result in the activation
of G protein. A tentative answer to this question was supplied by
the crystal structure of an agonist-bound b2AR in complex with a
nucleotide-free Gs heterotrimer (Rasmussen et al., 2011)
(Figure 1). The most pronounced, agonist-induced conforma-
tional change in b2AR is a 14 A˚ outward movement at the cyto-
plasmic end of TM6 and TM5. The conformational changes
induced by the interactions between b2AR and Gs are propa-
gated to the nucleotide-binding pocket, presumably facilitating
replacement of GDP by GTP. The most unanticipated change
is a marked displacement of the a-helical domain of Gas relative
to the Ras-like GTPase domain (Rasmussen et al., 2011).
Membrane Transport Proteins
A living cell constantly needs to uptake nutrients from the envi-
ronment and to expel metabolites and waste materials. This
extremely complex process is mediated by a very large number
of membrane transport proteins that can be classified into at
least four general types: channels or pores, facilitators, second-
ary active transporters, and primary active transporters. An on-
line database of membrane transport proteins (www.TCDB.
org) contains more than 10,000 unique protein sequences that
are classified into over 800 transporter families. Membrane pro-
teins of known three-dimensional structure are cataloged online
at http://blanco.biomol.uci.edu/mpstruc/. I do not intend to
comprehensively cover all known structures of transporters.
Rather, I will simply give a few representative examples.
Channels. The aquaporin family of channels, consisting of
the water-conducting aquaporins and the glycerol-conducting
aquaglyceroporins, plays an essential role in the regulation of
cellular osmolarity. Structural analysis of aquaporin-1 (AQP1) re-
vealed a tetrameric assembly and identified four water mole-
cules that are localized at three hydrophilic nodes along an
otherwise highly hydrophobic selectivity filter (Figure 4B), sup-
porting rapidwater transport (Sui et al., 2001). Subsequent struc-
tural analysis of aquaporin Z identified the molecular mechanism
for differentiation between water and glycerol by the aquaporin
family (Savage et al., 2003). Structure of the glycerol facilitator
GlpF revealed an amphipathic selectivity pore that is lined by a
number of glycerol molecules in single file (Fu et al., 2000). Struc-
tural analysis and molecular dynamics simulation elucidated the
molecular mechanism of selective permeability for glycerol (Fu
et al., 2000; Tajkhorshid et al., 2002). The aquaporin fold is
also observed in other small-molecule transporters such as the
pentameric formate channel FocA (Waight et al., 2010; Wang
et al., 2009).
Physical forces, in the form of touch, hearing, pressure, and
gravity, are primarily sensed by a family of mechanosensitive
ion channels, which transduce mechanical strain into an electro-
chemical response. The X-ray structure of the MscL, determined
at 3.5 A˚ resolution, revealed a homopentamer (Figure 4C) (Chang
et al., 1998). In each subunit, a water-filled opening at the extra-
cellular side is followed by a hydrophilic pore that narrows to an
occluded region at the cytoplasmic side. This structure serves as
a model system for understanding of and comparison with other
mechanosensitive channels. Structural analysis of the small-
conductance mechanosensitive channel (MscS) shows a hepta-
meric assembly, with the closed-state transmembrane pore
connecting to a large chamber in the cytoplasmic side (Bass
et al., 2002). Notably, the overall fold in the transmembrane re-
gion is different between MscL and MscS, with two TMs in
MscL and three TMs in MscS.
Chemical transmitters of excitatory synapses in the central
nervous system, exemplified by glutamate, activate receptors
on the postsynaptic cells, leading to transmission of signals
from one neuron to the next. Ionotropic glutamate receptors
(iGluRs) are ligand-gated ion channels. The iGluR family includes
AMPA, kainite, and NMDA receptors, which are heterotetrameric
or homotetrameric. Crystal structure of the homotetrameric
AMPA-type GluA2 receptor bound to a competitive antagonist
revealed a closed conformation, with a 2-fold symmetry in theextracellular domain and a 4-fold symmetry in the membrane-
spanning ion channel domain (Figure 4D) (Sobolevsky et al.,
2009). Structural analysis of the GluA2 receptor allowed propo-
sition of mechanisms for ion channel activation, desensitization,
and inhibition by noncompetitive antagonists. These mecha-
nisms were further investigated by the X-ray structure of GluA2
bound to cone snail toxin (Chen et al., 2014) and in distinct func-
tional states (Du¨rr et al., 2014). Structure of the NMDA-type, het-
erotetrameric receptor involving two GluN1 and two GluN2B
subunits confirmed some of the proposed general mechanisms
for iGluRs and provided additional insights (Karakas and Furu-
kawa, 2014; Lee et al., 2014).
Secondary Active Transporters. Unlike channels, transporters
never allow simultaneous substrate access from both sides of
the lipid membrane. A prevailing model for the general transport
mechanism is known as alternating access (Jardetzky, 1966),
which postulates that a transporter must switch between at least
two conformations: open to the extracellular side (outward-
open) for substrate upload and open to the intracellular side (in-
ward-open) for substrate release, or vice versa. Restrained by
a series of conformational switches within each transport cycle,
a transporter can only move 200–50,000 substrate molecules
per second, considerably slower than that for channels (which
sometimes can permeate substrates at near diffusion limit).
The ability to transport substrate molecules against their con-
centration gradients, together with the different conformational
states within each transport cycle, have made membrane trans-
porters appealing for structural and mechanistic investigations.
The major facilitator superfamily (MFS) transporters are ubiq-
uitously present in all kingdoms of life and play an important
role in numerous cellular processes. The first crystal structures
on MFS were reported on the lactose permease LacY from
E. coli (Abramson et al., 2003) and the glycerol-3-phosphate
transporter GlpT (Huang et al., 2003) (Figure 5A). The structures
revealed a conserved MFS fold of 2-fold symmetric N-domain
and C-domain, each comprising six consecutive TMs. The trans-
port path, as well as the substrate-binding site, is located be-
tween the N and C domains. The structural information provides
immediate explanation to a large body of biochemical and
biological observations, particularly on LacY (Kaback, 2005).
Distinct conformational states of MFS, which include the multi-
drug transporter EmrD (Yin et al., 2006), the L-fucose:H+ sym-
porter FucP (Dang et al., 2010), the peptide transporters PepTSo
and PepTSt (Newstead et al., 2011; Solcan et al., 2012), and the
D-xylose:H+ symporter XylE (Sun et al., 2012) appear to support
the alternating access model. Perhaps the best known and most
important MFS family members are the glucose transporters
GLUT1–4, which are associated with a number of debilitating
diseases. Crystal structure of the full-length human GLUT1—
the first eukaryotic MFS structure—allows rationalization of dis-
ease-derived mutations (Figure 5B) (Deng et al., 2014).
Crystal structure of the sodium:leucine symporter LeuT
revealed a conserved fold of ten TMs grouped into two inverted
repeats, each containing five consecutive TMs (Figure 5C)
(Yamashita et al., 2005). The first TM in each of the two inverted
repeats, TM1 or TM6, is discontinuous and contains a highly
conserved unwound segment that is positioned in the trans-
port path. A similar fold was subsequently observed in theCell 159, November 20, 2014 ª2014 Elsevier Inc. 1003
Figure 5. Structures and Mechanisms of
Representative Secondary Active Trans-
porters
(A) Crystal structure of the E. coli lactose
permease LacY. The overall structure of LacY is
shown in two perpendicular views (left and mid-
dle). The transport path is highlighted by a red
circle in the middle panel, and its close-up view is
shown in the right panel. Residues involved in
substrate binding and proton coupling are colored
magenta and red, respectively.
(B) Crystal structure of the human glucose trans-
porter GLUT1. Two amino acids forming the
extracellular gate are labeled in the close-up view.
(C) Crystal structure of the sodium symporter
LeuT. Arg30 and Asp404 are thought to play a key
role at the extracellular gate, whereas Arg5 and
Asp369 control the intracellular gate. These four
amino acids are indicated in the close-up view.nucleobase:cation symporter-1 family Mhp1 (Weyand et al.,
2008) and the solute sodium symporter family vSGLT (Faham
et al., 2008). Remarkably, despite lack of sequence or functional
conservation, the same general LeuT fold has been recognized in
several membrane transporter families, exemplified by the glyci-
ne:betaine transporter BetP (Ressl et al., 2009), and amino acid
antiporters AdiC and GadC (Fang et al., 2009; Gao et al., 2009,
2010; Ma et al., 2012). These unanticipated structural findings
led to reclassification of membrane transporters, with nine
LeuT-fold families now grouped together to constitute the APC
superfamily (Saier et al., 2009).
Primary Active Transporters. Primary active transporters,
exemplified by the sarco/endoplasmic Ca2+-ATPase (SERCA)
and the ATP binding cassette (ABC) transporters, exploit the en-
ergy of ATP binding and hydrolysis for substrate transport, usu-
ally against concentration gradient of the substrate molecules.
The 2.6 A˚ resolution crystal structure of SERCA1a revealed a
complex architecture, with two calcium ions bound in the mem-
brane spanning region (Figure 6A) (Toyoshima et al., 2000).
Structural comparison with the enzyme in the absence of cal-
cium suggests large domain movements during active transport,
which was confirmed by the structure of SERCA1a in a calcium-
free state (Toyoshima andNomura, 2002). The active transport of
calcium ion by this ATPase pump involves several distinct
conformation states. These conformational states were visual-
ized by a number of related crystal structures of SERCA,
including that bound to ATP or an ATP analog (Olesen et al.,
2007; Olesen et al., 2004; Sørensen et al., 2004; Toyoshima1004 Cell 159, November 20, 2014 ª2014 Elsevier Inc.and Mizutani, 2004), ADP (Sørensen
et al., 2004), and a phosphate analog
(Olesen et al., 2007; Toyoshima et al.,
2004). Together, these structures allow
mechanistic understanding of the com-
plete cycle of calcium transport driven
by ATP binding and hydrolysis.
An ABC transporter contains at least
four subunits: two transmembrane do-
mains (TMDs) and two ABCs (or nucleo-
tide binding domains, NBDs) located in
the cytoplasm. The first crystal structureof the ABC transporter—that of the tetrameric BtuCD complex
at 3.2 A˚ resolution—revealed a central translocation path that
is formed between two BtuC subunits within the membrane
and closed to the cytoplasmic side by a gate region (Figure 6B)
(Locher et al., 2002). This structure serves as a framework for
all subsequent structural investigations and mechanistic under-
standing. Crystal structures, including a bacterial multidrug
transporter Sav1866 (Dawson and Locher, 2006), a putative
metal-chelate-type transporter (Pinkett et al., 2007), a maltose
transporter (Oldham et al., 2007), BtuCD bound to the periplas-
mic-binding protein BtuF (Hvorup et al., 2007), a bacterial lipid
flippase MsbA (Ward et al., 2007), a molybdate/tungstate trans-
porter ModBC (Gerber et al., 2008), and amethionine transporter
(Kadaba et al., 2008), captured different conformational and
nucleotide-bound states. These snapshots allow proposition of
a complete transport cycle for an ABC transporter. The transport
cycle is elegantly shown for the maltose transporter MalFGK2,
with a number of conformational states observed at atomic de-
tails (Chen et al., 2013; Khare et al., 2009; Oldham and Chen,
2011a, 2011b; Oldham et al., 2007).
The energy-coupling factor (ECF) family of membrane trans-
porters shares a similar organization with the ABC transporters
with two NBDs and two TMDs. In contrast to the ABC trans-
porters, the two NBDs of an ECF transporter are encoded by
two different ATPase genes, and the two transmembrane do-
mains have contrasting roles, with one specific for substrate
binding (S component) and the other for energy transduction
(T component). Structures of the heterotetrameric ECF
Figure 6. Structures and Mechanisms
of Representative Primary Active Trans-
porters
(A) Crystal structure of the calcium ATPase SER-
CA1a. The structure of SERCA1a is displayed in a
rainbow-colored cartoon representation with its
amino-terminus in blue and carboxyl-terminus in
red (left). Three cytoplasmic domains, A, N, and P,
are labeled, and the transmembrane domain
consists of ten TMs. The calcium binding sites are
shown in a close-up view (right). Two calcium ions
are represented in magenta spheres.
(B) Crystal structure of the ABC transporter
BtuCD. BtuCD consists of four subunits, two
membrane-spanning subunits BtuC (purple and
blue), and two ABC subunits BtuD (cyan and
green). The transport path is closed to the cyto-
plasm by a gate region, with two residues Thr142
and Ser143 playing a key role.
(C) Crystal structure of a representative ECF
transporter. The structure of a tetrameric ECF
transporter is shown in two perpendicular views.
The TMs of the substrate-binding S component
(EcfS) are nearly parallel to the lipidmembrane and
perpendicular to those of the energy-transducing
T component (EcfT). The structural organization
revives the carrier model for membrane trans-
porters.transporters revealed a striking organization—the six TMs of the
S component are placed roughly parallel to the lipid membrane
and perpendicular to the TMs of the T component (Figure 6C)
(Wang et al., 2013; Xu et al., 2013). These structures, together
with results of MD simulation, strongly support the carrier model
of substrate transport (Widdas, 1952), which differs from the
alternating access model.
Intramembrane Proteases. Regulated intramembrane proteol-
ysis (RIP), which requires cleavage of a membrane-embedded
substrate protein by an intramembrane protease within the lipidCell 159, Nobilayer, is a universally conserved
signaling mechanism from bacteria to hu-
man beings (Brown et al., 2000). The
most remarkable examples of RIP include
cleavage of the cholesterol-controlling
transcription factor SREBP by the metal-
loprotease S2P, the cleavage of the
growth factor Spitz by the serine protease
rhomboid, and the cleavage of amyloid
precursor protein by the aspartate pro-
tease presenilin (which is the catalytic
component of the g-secretase). Unlike
proteases in aqueous environment, the
hydrophilic active site of an intramem-
brane protease must be accessible to
water molecules, which are required for
proteolysis, and substrate proteins within
the hydrophobic lipid membrane. Struc-
tural information is now available on the
bacterial homologs of the three classes
of intramembrane proteases, including
the rhomboid homolog GlpG from E. coli
(Ben-Shem et al., 2007; Lemieux et al.,2007; Wang et al., 2006; Wu et al., 2006), the archael S2P homo-
log (Feng et al., 2007), and the presenilin homolog PSH (Li et al.,
2013). In all cases, the active site has constant access to water
molecules through a funnel that opens either to the extracellular
side or the cytoplasmic side. This crystallographic finding is
elegantly simple yet completely unanticipated in the absence
of structural information. The active site is shielded from the hy-
drophobic membrane bilayer by one or two gating TMs, which
undergo lateral rotation or movement to allow substrate entry.
For GlpG, the gating helix TM5 had been captured in fullyvember 20, 2014 ª2014 Elsevier Inc. 1005
open, partially open, and closed conformations. The recent cryo-
EM structure of human g-secretase (Lu et al., 2014), along with
the X-ray structure of its putative substrate-recruiting compo-
nent nicastrin (Xie et al., 2014), revealed tantalizing clues about
functional mechanisms of g-secretase.
Method Development
Protein Expression and Purification
Prior to 1970s, all proteins employed for X-ray crystallography
were derived from endogenous sources—mostly animal tissues
and organs—and were biochemically purified. These proteins,
exemplified by myoglobin and lysozyme, are thermodynamically
stable and contain few flexible surface sequences that may
hinder crystallization. In late 1970s, discovery of the restriction
enzymes greatly facilitated cloning of target cDNA into plasmids,
allowing recombinant expression in E. coli. Unfortunately, many
recombinant proteins, especially those containing multiple do-
mains and/or flexible surface sequences, defied crystallization.
Finding a crystallizable protein domain or fragment frequently
required multiple trials of protein engineering, each involving
different boundaries or mutations for the target protein. Limited
proteolysis has been used to identify stable core domains that
are amenable for crystallization. One of the most remarkable ex-
amples of limited proteolysis was the identification of sequence
boundaries for the DNA-binding domain of p53 (Pavletich et al.,
1993).
Recombinant coexpression of two or more proteins became a
popular strategy in the 1990s. This strategy allowed convenient
assembly of multicomponent protein complex. Although bacte-
rial expression is fast and inexpensive, eukaryotic proteins are
frequently misfolded or aggregated when expressed in bacteria,
likely due to differences in folding environment. Eukaryotic re-
combinant expression systems, involving yeast, baculovirus-in-
fected insect cells, and mammalian cells, play an increasingly
more important role (Assenberg et al., 2013). For mammalian
cell expression, both stable cell lines and transient expression
through plasmids have succeeded in production of large quanti-
ties of materials for crystallization. Stable CHO cells allowed
expression and purification of milligram quantity of g-secretase,
a four-component membrane protein complex (Alattia et al.,
2013).
Crystallization
Until early 1990s, approximately half of all crystals were ge-
nerated with ammonium sulfate as the major precipitant in the
crystallization buffer. In the year 2013, however, none of the 55
crystal structures reported in the journal Nature relied on ammo-
nium sulfate as a crystallization agent. This dramatic change
likely reflects the proposition that ammonium sulfate may work
better for small protein of greater thermal stability. Perhaps
more importantly, the reagents and tools for crystallization
have steadily improved in the last two decades, including
numerous commercial reagent kits, robotic arms, and develop-
ment of special methodology for membrane protein crystalliza-
tion (McPherson and Gavira, 2014). The lipidic cubic phase
(LCP) has been widely used for the crystallization of membrane
proteins (Caffrey, 2009), with fantastic successes for GPCRs
(Cherezov et al., 2010). Bicelles were also applied to membrane
protein crystallization (Agah and Faham, 2012).1006 Cell 159, November 20, 2014 ª2014 Elsevier Inc.Although prior experience may facilitate crystallization of a
new target protein or macromolecular complex, systematic
screening of representative crystallization space is almost al-
ways recommended. In all cases of difficult proteins, biochem-
istry and molecular biology are the keys for crystallization—
that is, improvement of solution behavior through biochemical
characterization and extensive protein engineering. Insertion of
a T4 lysozyme into b2AR proved to be important for improve-
ment of crystal packing and hence X-ray diffraction limit (Rose-
nbaum et al., 2007). Sequence alignment among homologous
proteins frequently yields valuable hints on how to improve the
chance of crystallization. For example, replacing five noncon-
served amino acids with conserved ones led to crystallization
of a presenilin homolog (Li et al., 2013). The crystallization of
the AMPA-type receptor GluA2 required carboxyl-terminal and
internal deletion, removal of potential glycolysation sites, alanine
substitution, and specific mutation (Sobolevsky et al., 2009).
Structure Determination
Since the invention of the oscillation/rotation protocol (Arndt and
Wonacott, 1977), it has quickly become the primary X-ray dif-
fraction data collection method on single crystals. Powerful
rotating anode generators have been improved continuously to
generate X-rays with high intensity. Synchrotron radiation, which
supplies X-rays with tunable wavelength and much higher X-ray
flux than home source, was brought to the attention of biological
crystallographers (Rosenbaum and Holmes, 1971) and quickly
became an intimate partner of structural biology. Fast-readout
large-area X-ray detectors have been critically important for
data collection. Synchrotron beamlines are provided with
charge-coupled detectors (CCDs), which make data collection
much faster and more accurate than ever before (Phillips et al.,
1993). More recently, the concept of shutter-free data collection
has been made possible by the pixel array detectors (Pilatus 6M)
(Kraft et al., 2009). Cryogenic protection by flash freezing crys-
tals at 100 K greatly reduced radiation damage (Rodgers,
1994), which allows complete data collection from a single crys-
tal, instead of data merging from multiple crystals in the past.
Software for X-ray data collection and processing, structure
determination, and model building has seen major improvements
in the last two decades. Most notably, structure determination
based on a single crystal became possible with development of
themultiwavelength anomalous diffraction (MAD)method (Phillips
and Hodgson, 1980; Yang et al., 1990). The ease of selenome-
thione incorporation into recombinant proteins and the powerful
synchrotron radiation have made MAD the preferred method for
de novo protein structure determination. Ribonuclease H was
the first protein whose structure was successfully determined
by selenium-based MAD analysis (Yang et al., 1990). Free R fac-
tor, introduced as an objective criteria for structural cross-valida-
tion (Bru¨nger, 1992), prevents overrefinement and has quickly
become a key parameter for all X-ray structures. Free R factor
was also instrumental to implementation of maximum likelihood
target functions in crystallographic programs (Pannu and Read,
1996). In 1994, the CCP4 (collaborative computational project,
number 4) suite was established, which collected a number of
programs for various macromolecular structure determination
methods by X-ray crystallography (Collaborative, 1994). Another
structure determination package CNS (Bru¨nger et al., 1998),
superseded by PHENIX (Adams et al., 2002), not only provides all
necessary programs for X-ray structure solution but also incorpo-
rates the refinement method of simulated-annealing after X-plor
(Brunger, 1990). Structural genomics demanded high-throughput
crystallography, with a number of automated structure solution
pipelines established worldwide through integration of existing
programs for automation.
The use of MIR demands generation of heavy atom derivatives
of the crystals. The heavy atom agents ‘‘magic seven’’ (Boggon
and Shapiro, 2000) and ‘‘membrane’s eleven’’ (Morth et al.,
2006) were recommended for crystals of soluble and membrane
proteins, respectively. Polynuclear metal clusters were utilized
for phasing of larger protein complexes (Dauter, 2005), exempli-
fied by the ribosomal large subunit (Ban et al., 2000). Compared
to heavy metals, bromide or iodine ions can be quickly soaked
into protein crystals within minutes. In addition to MIR and
MAD, mainstream experimental phasing methods also include
single-wavelength anomalous dispersion (SAD), single isomor-
phous replacement (SIR), multiple isomorphous replacement
with anomalous scattering (MIRAS), and single isomorphous
replacement with anomalous scattering (SIRAS). Molecular
replacement (MR) is used for phasing with a homologous model.
Automated model-building algorithms and molecular modeling
graphics such as COOT (Emsley and Cowtan, 2004), preceded
by O (Jones et al., 1991), have greatly accelerated the pace of
structure determination.
Prior to the mid-1990s, it wasn’t uncommon for a PhD student
in an X-ray crystallography laboratory to spend 3 to 4 years to
solve the phase problem, requiring understanding of Patterson
maps and resolution of the Harker sections. Consequently, stu-
dents then usually needed to have certain knowledge of mathe-
matics and physics. Nowadays, a student only needs to mount
crystals correctly in the X-ray beam, and the rest—data collec-
tion and structure determination—can be just a few clicks
away. Intense X-rays at various synchrotron facilities have not
only greatly expanded our investigative power on small and
weakly diffracting crystals but have also made high-throughput
crystallography a reality (Joachimiak, 2009). Remote control of
data collection at synchrotrons has eased the trouble of long-
distance traveling and sleepless night fatigue.
Hard X-Ray Free Electron Laser
For most X-ray beamlines in existing synchrotrons, destruction
of crystals by radiation damage accompanies the process of
data collection. Ultrashort (femtoseconds), high-intensity X-ray
pulses from free-electron lasers were predicted to provide useful
structural information before the destruction of the sample by ra-
diation damage (Neutze et al., 2000). This prediction was
reached on the basis of computer simulation of radiation dam-
age, taking into account photon energy, pulse length and inten-
sity, and sample size. A decade later, the proof of concept was
established with image construction on diffractions collected
on individual virus particles (Seibert et al., 2011) and an electron
density map at 8.5 A˚ resolution of photosystem I, which required
millions of nanocrystals andmore than 3,000,000 diffraction pat-
terns (Chapman et al., 2011). Both studies were carried out at the
Linac Coherent Light Source at Stanford University, which offers
the world’s first hard X-ray free electron laser (XEFL) with an
X-ray intensity of 1012 photons in 10 femtoseconds, or about10–13 orders of magnitude more intense than a regular third-
generation synchrotron. The first high-resolution X-ray structure
by serial femtosecond crystallography (SFX) was accomplished
on lysozyme (Boutet et al., 2012), followed by de novo generation
of experimental phases for lysozyme (Barends et al., 2014). This
technology has been successfully applied to structure deter-
mination of a precursor cathepsin B (Redecke et al., 2013),
photosystem II (Kern et al., 2013), and a human serotonin recep-
tor (Liu et al., 2013).
The breathtaking advances of XFEL-based SFX rely on devel-
opment of container-free sample spraying techniques, with initial
crystal hit rate of less than 0.01%. Thus, a vast number of nano-
crystals were a prerequisite for such technology, although
improvement is underway. By design of the SFX technology, all
X-ray diffraction patterns collected are still, partial images, which
demand improvements in data processing software (Hattne
et al., 2014). The fact of one image per crystal also mandates
the isomorphous nature of the microcrystals. These challenges,
together with the exceedingly high costs associated with con-
struction of XFEL facility, may qualify the near-future application
of SFX to limited pragmatic impact. Nonetheless, as the ultimate
technology for determination of macromolecular structure in
aqueous solution at room temperature, XFEL is destined to domi-
nate in the future.
Molecular Dynamics
Crystal structures represent static snapshots of macromole-
cules—averaged temporally and spatially over myriad of subtle
conformational differences. In real life, however, these mole-
cules may interconvert among a few distinct conformations to
accomplish their biological functions. Thankfully, these distinct
conformational states can be trapped by alteration of crystalliza-
tion condition, inclusion of specific ligand, and/or mutation of
specific amino acids. At times of difficulty in capturing one or
more of these conformational states, molecular dynamics (MD)
simulation came to the rescue. A super machine named Anton
extended the timescale of MD simulation to millisecond and
therefore enabled the observation of large-scale conformational
changes of macromolecules in silico (Lindorff-Larsen et al.,
2011; Shaw et al., 2010). Using this approach, the transition be-
tween different conformational states was observed for a num-
ber of proteins.
In addition to identifying putative conformational changes, MD
simulation also helps reveal insights that are sometimes unnoted
by structural analysis. Simulation of the c-Src and Hck kinases
revealed an important role for the linker sequence between
SH3 and SH2 domains, which helps maintain the kinases in an
inhibited state (Young et al., 2001). 12 ns MD simulations of the
aquaglyceroporin GlpF identified the spatial and temporal prob-
ability distribution of a single file of seven to nine water molecules
and defined their orientation inside the channel, which mecha-
nistically explained the impermeability of aquaporin to protons
(Tajkhorshid et al., 2002). Themolecular mechanism of ion selec-
tivity, K+ versus Na+, in potassium channels was rationalized by
molecular simulation and theoretical computation (Bostick and
Brooks, 2007; Noskov et al., 2004).
Time-Resolved X-Ray Crystallography
Conformational dynamics of macromolecules, especially those
in enzyme reactions, can be captured by time-resolved X-rayCell 159, November 20, 2014 ª2014 Elsevier Inc. 1007
crystallography, which uses intense, polychromatic X-ray pulses
to generate Laue diffraction from a single crystal upon induction
of light-initiated reaction (Neutze and Moffat, 2012). A classic
example is observation of photodissociation and rebinding of
carbon monoxide to myoglobin and hemoglobin (Knapp et al.,
2006; Srajer et al., 1996). These time-resolved findings identify
myoglobin photoproducts and serve a structural basis to spec-
troscopic observations and MD calculations. Technical chal-
lenges specific for Laue diffraction such as overlap of energies
and spots have been effectively dealt with. Maturation of time-
resolved X-ray crystallography allowed its application in fragile
membrane protein crystals, as evidenced by the direct observa-
tion of light-induced changes in a photosynthetic reaction center
(Burgess et al., 2003). The emergence of XFELs is transforming
the field of time-resolved X-ray crystallography, despite nu-
merous unresolved challenges. In contrast to time-resolved
Laue diffraction, which requires crystals, time-resolved wide-
angle X-ray scattering (WAXS) allows study of macromolecules
in solution and has been successfully applied to a number of pro-
teins, including myoglobin and hemoglobin.
Concluding Remark
X-ray crystallography seemed to be at its pinnacle in the early
1990s, when I, as a motivated graduate student, felt extremely
excited by the rapid emergence of crystal structures on biologi-
cally important macromolecules. The forecast was that structural
biology by X-ray crystallography would become saturated within
a few years, leaving structural biologists in an awkward situation
of excess in supply. Another prediction, believed by many in the
late 1990s, would have structural genomics—automated high-
throughput X-ray crystallography—dominate the research land-
scape. Thankfully, neither prediction was remotely close to fact.
X-ray crystallography is alive and well and continues to play an
extremely important role in deciphering the secrets of life. In
essence, life is all about function and structure, with the former
determined by the latter. In the past five decades, structural
biology through X-ray crystallography has provided important
mechanistic insights into every discipline ofmodern experimental
biology. A large proportion of all display items in the seventh edi-
tion of the Jeremy Berg and Lubert Stryer Biochemistry textbook
are structural images, mostly derived from X-ray crystallographic
analyses. X-ray crystallography is at its pinnacle. What follows
pinnacle must be a downhill path—would this be true for X-ray
crystallography?
In response to a question raised by a motivated, biophysics-
oriented student, Doug Rees of Caltech commented at a special
seminar at the end of 2013 that ‘‘If I were to choose a lab to join
for my PhD thesis research, I would probably go for an EM lab.’’
This statement echoes the emotions of those structural biolo-
gists who have been so comfortable with X-ray crystallography
as the method of choice for elucidating three-dimensional struc-
tures of macromolecules. The recent technological advances in
cryo-EM, single-particle analysis have sent shockwaves through
the entire structural biology community. Near-atomic resolution
EM structures have been obtained not only for the megacom-
plexes such as ribosomes and viruses (Amunts et al., 2014;
Zhang et al., 2010) but also for relatively small protein particles
exemplified by the TRP channel (Liao et al., 2013). Recently, a1008 Cell 159, November 20, 2014 ª2014 Elsevier Inc.4.5 A˚ resolution density map was generated for human g-secre-
tase (Lu et al., 2014), which has a calculated protein molecular
weight of only 160 kDa with no symmetry. In the 1990s, the
Cold Spring Harbor Laboratory Course on X-ray Crystallography
was extremely popular for NMR spectroscopists. That signaled a
trend that is still unfolding today. In the 2014 Kuo KH Summer
School of Electron Microscopy in Shanghai, a number of estab-
lished X-ray crystallographers were enrolled as students. There
is no doubt that a new trend is in place and will change the
pace of structural biology for many years to come.
John Burdon Sanderson Haldane, one of the greatest evolu-
tionary biologists of all times, once declared in his essay, The
Future of Biology, that ‘‘. the future will make any detailed pre-
dictions look rather silly.’’ Indeed, the eternal truth in research is
that the unexpected always happens. Within the past 2 years,
cryo-EM has emerged as a competitive and perhaps even
more favored tool for elucidation of macromolecular assemblies
with molecular weight of more than 300 kDa. In the foreseeable
future, advances in sample preparation and image acquisition
will likely expand the advantages of cryo-EM over X-ray crystal-
lography into complexes with smaller molecular weights. On the
other hand, technological development of XFEL may strongly
affect the comparison of EM versus X-ray. After all, the ultimate
goal of XFEL is to make reconstruction of single-molecule scat-
tering possible, namely to visualize single molecules with atomic
details in solution. Regardless of these scenarios, X-ray crystal-
lography will continue to dominate structure determination for
many years to come, owing to its mature methodology, high res-
olution, convenient accessibility worldwide, and a vast number
of experienced users.
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